

LEARN MORE ON OUR VENTURE'S STAGES




Figure 5.2 Number of years our ventures needed to get to the market in 2022 and 2023

This year, 17 of our ventures have made progress in terms of Technology Readiness Level (TRL) steps. Notably, 6 ventures have entered the clinical trials stage and over 11 ventures are preparing to commence their clinical trials in 2024, which is an important step as the clinical trials will demonstrate the real impact of the product. The products of, amongst others, Flash Pathology, Angiogenesis Analytics, POROUS, Intuescope and Bilihome are currently being tested in clinical studies.

Additionally, nine of our ventures are actively selling their products. On average, it took these ventures 2.9 years from being added to our portfolio to sell their first product. This marks a slight improvement from last year's average of 0.2 years. The expedited timeline can be attributed to the presence of digital ventures in our portfolio. Unlike traditional medtech or biotech inventions, these digital ventures do not require extensive clinical trials, allowing them to bring their products to market more swiftly.